Literature DB >> 36127544

Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.

Karlijn Verkerk1, Hans-Martin Otten2, Alwin D R Huitema3,4,5.   

Abstract

Idiopathic hyperammonemic encephalopathy is a rare complication of chemotherapy, which has previously mainly been associated with L-asparaginase, cytarabine and 5-FU. We present a case following treatment with gemcitabine-cisplatin in a patient with cholangiocarcinoma. The etiology of chemotherapy-induced idiopathic hyperammonemic encephalopathy remains unclear and existing theories differ per chemotherapeutic agent. Physicians treating patients with gemcitabine-cisplatin should be aware of the possibility of this complication, especially because it is treatable when recognized early.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cisplatin; Gemcitabine; Hyperammonemia; Hyperammonemic encephalopathy

Mesh:

Substances:

Year:  2022        PMID: 36127544     DOI: 10.1007/s00280-022-04476-6

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.288


  12 in total

1.  A fatal case of cholestatic liver failure probably related to gemcitabine.

Authors:  D C Coeman; E K Verbeken; K L Nackaerts; M G Demedts; J F Vansteenkiste
Journal:  Ann Oncol       Date:  2000-11       Impact factor: 32.976

2.  Fatal hepatic failure due to gemcitabine and vinorelbine.

Authors:  K Kagohashi; Y Funayama; H Satoh; K Sekizawa
Journal:  Ann Oncol       Date:  2003-06       Impact factor: 32.976

3.  Acute liver failure secondary to gemcitabine.

Authors:  Alice Stellman; Mei Mei Loke; Steven Mann
Journal:  BMJ Case Rep       Date:  2010-04-22

4.  Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia.

Authors:  Yu-Hsien Chen; Tzeon-Jye Chiou; Yen-Ning Hsu; Chun-Yu Liu
Journal:  Hematol Oncol Stem Cell Ther       Date:  2010

5.  A fatal case of progressive steatohepatitis, possibly chemotherapy-associated steatohepatitis related to gemcitabine.

Authors:  Xiang Shan Ren; Kenichi Harada; Seiichi Yoshikawa; Saya Igarashi; Takeshi Urabe; Shinya Yamada; Kazuyoshi Katayanagi; Hiroshi Kurumaya; Yasuni Nakanuma
Journal:  Clin J Gastroenterol       Date:  2010-06-22

6.  Fatal cholestatic liver failure associated with gemcitabine therapy.

Authors:  Keith Robinson; Louis Lambiase; Jianjun Li; Carmela Monteiro; Michael Schiff
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

Review 7.  Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy.

Authors:  Louise Nott; Timothy J Price; Ken Pittman; Kevin Patterson; Janice Fletcher
Journal:  Leuk Lymphoma       Date:  2007-09

8.  Hepatic encephalopathy associated with cancer or anticancer therapy.

Authors:  Kaspar J Willson; Louise M Nott; Vy T Broadbridge; Timothy Price
Journal:  Gastrointest Cancer Res       Date:  2013-01

Review 9.  Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review.

Authors:  Joon Oh Park; Do-Youn Oh; Chiun Hsu; Jen-Shi Chen; Li-Tzong Chen; Mauro Orlando; Jong Seok Kim; Ho Yeong Lim
Journal:  Cancer Res Treat       Date:  2015-05-18       Impact factor: 4.679

10.  Oxaliplatin-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Pancreatic Cancer: A Case Report.

Authors:  Takatsugu Ogata; Hironaga Satake; Misato Ogata; Yukimasa Hatachi; Hisateru Yasui
Journal:  Case Rep Oncol       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.